Regístrese
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) PTPN22 −1123G>C polymorphism and anti-cyclic citrullinated protein antibodies ...
Journal Information
Vol. 149. Issue 3.
Pages 95-100 (August 2017)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 149. Issue 3.
Pages 95-100 (August 2017)
Original article
DOI: 10.1016/j.medcle.2017.06.026
PTPN22 −1123G>C polymorphism and anti-cyclic citrullinated protein antibodies in rheumatoid arthritis
Polimorfismo −1123G>C en el gen PTPN22 y anticuerpos antipéptido citrulinado cíclico en la artritis reumatoide
Visits
0
José Francisco Muñoz-Vallea,
Corresponding author
biologiamolecular@hotmail.com

Corresponding author.
, Jorge Ramón Padilla-Gutiérreza, Jorge Hernández-Belloa, Yeniley Ruiz-Noaa, Yeminia Vallea, Claudia Azucena Palafox-Sáncheza, Isela Parra-Rojasb, Sergio Ramón Gutiérrez-Ureñac, Hector Rangel-Villalobosd
a Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
b Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, Mexico
c Servicio de Reumatología, OPD Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
d Instituto de Investigación en Genética Molecular, Centro Universitario de la Ciénega, Universidad de Guadalajara, Ocotlán, Jalisco, Mexico
This item has received
0
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (4)
Table 1. Demographic and clinical characteristics of RA patients.
Table 2. Distribution of PTPN22 −1123G>C polymorphism among RA patients and CS.
Table 3. Genotypic and allelic frequencies of PTPN22 −1123G>C polymorphism in RA patients according to the seropositivity for anti-CCP antibodies.
Table 4. The world-wide distribution of allelic and genotypic frequencies at PTPN22 −1123 locus in CS.
Show moreShow less
Abstract
Background and objectives

The protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene encodes an important negative regulator of T-cell activation, lymphoid-specific phosphatase – Lyp – and has been associated with different autoimmune disorders. The PTPN22 −1123G>C polymorphism appears to affect the transcriptional control of this gene, but to date, the biological significance of this polymorphisms on rheumatoid arthritis (RA) risk remains unknown. We evaluate the association of PTPN22 −1123G>C polymorphism with anti-cyclic citrullinated protein antibodies (anti-CCP) and risk for RA in population from Western Mexico.

Materials and methods

A transversal analytic study, which enrolled 300 RA patients classified according to ACR-EULAR criteria and 300 control subjects (CS) was conducted. The −1123G>C polymorphism was genotyped by PCR-RFLP. The anti-CCP antibodies levels were quantified by ELISA kit.

Results

We found a higher prevalence of homozygous PTPN22 −1123CC genotype in CS than in RA patients (OR 0.41; 95% confidence interval 0.24–0.71; p=0.001), suggesting a potential protective effect against RA. Concerning anti-CCP levels, the CC genotype carriers showed the lowest median levels in RA (p<0.05).

Conclusion

The PTPN22 −1123CC genotype is a protector factor to RA in a Mexican-mestizo population and is associated with low anti-CCP antibodies.

Keywords:
Rheumatoid arthritis
PTPN22
Lymphoid-specific phosphatase (Lyp)
Anti-cyclic citrullinated protein antibodies
Resumen
Introducción y objetivos

El gen de la proteína tirosina fosfatasa no receptora de tipo 22 (PTPN22) codifica la proteína linfoide tirosina fosfatasa – Lyp – un importante regulador negativo de la activación de células T, que se ha asociado a distintos trastornos autoinmunitarios. El polimorfismo −1123G>C en el gen PTPN22 parece afectar al control de la transcripción de este gen, pero hasta la fecha, la importancia biológica sobre su contribución al riesgo de desarrollar artritis reumatoide (AR) sigue siendo desconocida. En el presente estudio evaluamos la asociación del polimorfismo −1123G>C con anti-cyclic citrullinated protein antibodies (anti-CCP, «anticuerpos antipéptido citrulinado cíclico») y el riesgo de desarrollar AR en la población del occidente de México.

Materiales y métodos

Se realizó un estudio transversal analítico, en el que participaron 300 pacientes con AR clasificados de acuerdo con los criterios del ACR-EULAR y 300 sujetos control (SC). El polimorfismo −1123G>C se genotipificó mediante PCR-RFLP. Los niveles de anticuerpos anti-CCP fueron cuantificados mediante una prueba de ELISA.

Resultados

Encontramos una mayor prevalencia de genotipos homocigotos CC en SC en comparación con los pacientes con AR (OR 0,41; intervalo de confianza del 95% 0,24–0,71; p=0,001), lo que demuestra un posible efecto protector contra la AR. En cuanto a los niveles de anti-CCP, los portadores del genotipo CC mostraron los niveles más bajos en el grupo de AR (p<0,05).

Conclusión

El genotipo CC del polimorfismo −1123G>C en el gen PTPN22 es un factor protector para la AR en la población mestiza mexicana y se asocia con niveles bajos de anticuerpos anti-CCP.

Palabras clave:
Artritis reumatoide
PTPN22
Proteína linfoide tirosina fosfatasa (Lyp)
Anticuerpos antipéptido citrulinado cíclico

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.